Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10899905 | Cancer Letters | 2013 | 7 Pages |
Abstract
This study aims to determine the effect of metronomic (0.0125Â mg/kg twice a week for 4Â weeks) zoledronic acid (ZOL) on cancer propagation and osteolysis against both metastatic and primary breast cancer in mice model. From our results, metronomic ZOL resulted in a significant reduction of tumor burden and did not promote lung or liver metastasis. The metronomic ZOL appeared to be more effective than the conventional regimen (0.1Â mg/kg once in 4Â weeks) in reducing breast cancer tumor burden, and regulating its movement to lung and liver. This dosing schedule of ZOL showed great potential against metastatic breast cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Ke-Wang Luo, Chun-Hay Ko, Grace G.L. Yue, Michelle Y.Y. Lee, Wing-Sum Siu, Julia K.M. Lee, Wai-Ting Shum, Kwok-Pui Fung, Ping-Chung Leung, Gang Li, Andreas Evdokiou, Clara B.S. Lau,